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We evaluated titers of homotypic and heterotypic neu-
tralizing antibodies (NAbs) to Andes and Sin Nombre han-
taviruses in plasma samples from 20 patients from Chile
and the United States. All but 1 patient had high titers of
NAb. None of the plasma samples showed high titers
against the heterologous virus. 
H
antavirus cardiopulmonary syndrome (HCPS), an
emergent disease caused by New World hantaviruses,
is associated with case-fatality ratios of 30% to 50%. Sin
Nombre virus (SNV) and Andes virus are well-character-
ized hantavirus serotypes responsible for this disease in the
southwestern United States and in the south cone of the
Americas (Argentina, Brazil, and Chile), respectively (1).
Since their recognition in 1993, they have caused hundreds
of cases, many of them appearing in seasonal outbreaks.
Other types of hantaviruses have been identified in the
Americas during the past decade, causing diseases with
variable severity. All of them are associated with different
rodent hosts of the subfamily Sigmodontinae, family
Muridae, and the distribution of each virus parallels that of
the host (2).
No specific treatment for HCPS exists. Ribavirin, the
only approved antiviral agent that is effective against han-
taviruses in vitro (3), has shown efficacy in treating hem-
orrhagic fever with renal syndrome, a related disease that
is caused by hantaviruses indigenous to the Old World (4).
However, technical difficulties prevented a trial that was
designed to evaluate the efficacy of ribavirin in treating
HCPS from being completed (5).
Some evidence shows that neutralizing antibody (NAb)
can affect the course of HCPS. Animal studies have shown
that NAb confers passive protection from severe disease
by Andes virus. Specifically, passive transfer of serum
with high NAb titers from rhesus macaques vaccinated
against Andes virus protected 100% of Syrian hamsters
from lethal disease, even when administered 4–5 days after
challenge with Andes virus (6). In humans, a high NAb
titer on hospital admission is correlated with less severe
HCPS (7)
Administering convalescent-phase plasma with a high
NAb titer could be therapeutic in HCPS, as it is in other
hemorrhagic fevers (8). In survivors of Sin Nombre infec-
tion, high titers of serum NAb could still be detected years
after recovery, with no evidence of residual viral RNA in
the plasma (9).
The severity of HCPS, the absence of effective treat-
ment, its appearance in outbreaks and in case-clusters, and
the potential use of hantaviruses as bioweapons have stim-
ulated work toward hantavirus vaccine development. At
present, an inactivated Hantaan virus vaccine is in use for
persons at high risk for exposure to Old World hantavirus-
es, but its efficacy has recently been questioned (10). A
DNA vaccine expressing the G1 and G2 glycoproteins
encoded by the Hantaan virus M segment conferred steril-
izing cross-protection against the other Old World han-
taviruses, Seoul, Dobrava, and Puumala, in hamsters (11).
For New World hantaviruses, in the hamster model for
Andes disease, prior infection with widely disparate
species conferred varying levels of cross-protection
(12,13). Although these selected studies suggest some
cross-protection among different hantavirus species, the
considerable antigenic variation among members of the
genus Hantavirus suggests that a monovalent vaccine will
not likely confer sufficient protection for all of the patho-
genic hantaviruses (14).
The persistence of NAb in plasma of survivors of Andes
virus and SNV infections, as well as the in vitro cross-neu-
tralization capacity of these NAbs against the heterotypic
hantavirus, could have implications for use of convales-
cent-phase plasma to treat HCPS. For vaccine develop-
ment, an evaluation of the duration of persistence of NAb
and their cross-neutralization activities across different
serotypes of hantaviruses would shed light upon the proba-
bility of obtaining satisfactory cross-protection among can-
didate vaccines against New World hantaviruses.
The Study
We studied 20 serum samples from survivors of con-
firmed hantavirus infection, 11 from Chilean patients and
9 from patients in the southwestern United States. Samples
were collected from 8 months to 11 years after the patient
was hospitalized with HCPS. The neutralizing titer was
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a focus-reduction neutralization assay in Vero E6 cells, as
described previously (7). In brief, serial 2-fold dilutions of
heat-inactivated patient plasma samples were made, from
1:100 to 1:1,600, and were mixed with equal volume of
≈50–100 focus-forming units per milliliter SNV (isolate
SN77734, titer 2 × 106/mL) or Andes virus (Chilean strain
of human origin, isolate CHI-7913) and incubated at 37°
for 1 hour (15). The mixture was then used to infect a con-
fluent monolayer of Vero E6 cells (ATCC CRL 1586) in
duplicate wells of a 48-well dish, with a 1.2% methylcel-
lulose overlay in the medium to confine the virus to the
foci. After incubation for 1 week, viral foci were detected
with polyclonal rabbit anti-N antibody followed by perox-
idase-conjugated goat anti-rabbit immunoglobulin G. Foci
were enumerated under an inverted light microscope. NAb
titers were defined as the reciprocal of the highest serum
dilution that resulted in an 80% reduction in the number of
foci compared to virus controls in duplicate assays. 
The endpoint plasma NAb titers against Andes virus
and SNV from Chilean and North American survivors of
hantavirus infection are shown in the Table. All Chilean
patients had detectable plasma NAb against Andes virus,
with titers >1:400 in all but 1 patient. In contrast, 9 of the
11 samples failed to show NAb titers >1:100 against SNV,
while the other 2 neutralized SNV only at low titers.
Similarly, all North American patients had plasma NAb
against SNV at titers >400, and only 1 showed some neu-
tralization against Andes virus, at low titer. No relationship
was seen between the endpoint NAb titers against the
homotypic virus and time elapsed from acute disease in
either Chilean or North American patients, nor did a par-
ticularly high homotypic titer predict that neutralizing
activity would be present against the heterologous virus.
Conclusions
In survivors of hantavirus disease who reside in Chile
or the United States, we found high titers of plasma NAb
against the type of hantavirus that is prevalent in the
patient’s own region, while substantial titers against the
heterologous agent of HCPS were absent. In this small
group of participants, NAb titers did not show any readily
detectable decline with time elapsed after infection; titers
as high as 1:1,600 could be detected 11 years after illness.
These results suggest that plasma from patients who sur-
vive hantavirus infection is a potential source of NAb and
could be used as a therapeutic alternative for patients with
acute disease or as a prophylactic intervention for persons
who may have been exposed to the virus. The absence of
in vitro cross-neutralization makes the alternative of clini-
cally effective cross-protection less likely and discourages
the use of convalescent-phase sera to treat patients whose
geographic origin is different from that of the plasma
donor. Our results suggest that a monovalent vaccine
would not elicit protection against different types of han-
tavirus, even when the viruses are phylogenetically as sim-
ilar as SNV and Andes virus. The positive results of
cross-protection studies in hamster models should be inter-
preted cautiously, since experimental infection in those
studies would tend to favor unusually brisk immune
responses that go well beyond eliciting NAb and likely
include potent cell-mediated or innate immune responses
that cannot be mimicked with passive immunization (12).
Similarly, some component of the cross- protective effica-
cy observed with genetic immunizations with hantavirus
envelope genes may ultimately be related to T-cell immu-
nity (13). From this perspective, either multivalent or
region-specific vaccines may have to be developed to pro-
tect persons at high risk from this new, relatively infre-
quent, but still highly lethal disease. 
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